{"id":6501,"date":"2023-03-03T00:33:15","date_gmt":"2023-03-03T00:33:15","guid":{"rendered":"\/\/smallcapscn.x5view.co\/?p=6501"},"modified":"2023-08-29T17:57:11","modified_gmt":"2023-08-29T17:57:11","slug":"incannex-healthcare-engages-catalent-develop-psilocybin-drug-clinical-trials-commercialisation","status":"publish","type":"post","link":"https:\/\/smallcapscn.x5view.co\/?p=6501","title":{"rendered":"Incannex Healthcare \u9501\u5b9a\u81ea\u5df1\u7684\u88f8\u76d6\u83c7\u7d20\u836f\u7269\u4f9b\u5e94\uff0c\u7528\u4e8e\u4e34\u5e8a\u8bd5\u9a8c\u548c\u6f5c\u5728\u5546\u4e1a\u5316"},"content":{"rendered":"<p>Incannex Healthcare (ASX: IHL) \u901a\u8fc7\u8058\u8bf7 Catalent \u6765\u914d\u5236\u548c\u5236\u9020\u7528\u4e8e\u4e34\u5e8a\u8bd5\u9a8c\u7684\u836f\u7269\uff0c\u4ece\u800c\u5728\u5f00\u53d1\u88f8\u76d6\u83c7\u7d20\u836f\u7269\u4ea7\u54c1\u65b9\u9762\u8fbe\u5230\u4e86\u53e6\u4e00\u4e2a\u91cc\u7a0b\u7891\u3002<\/p>\n<p>Incannex \u8fd8\u8868\u793a\uff0c\u5728\u6fb3\u5927\u5229\u4e9a\u76d1\u7ba1\u673a\u6784\u6cbb\u7597\u5546\u54c1\u7ba1\u7406\u5c40 (TGA) \u4ece\u4eca\u5e74 7 \u6708 1 \u65e5\u5f00\u59cb\u5c06\u88f8\u76d6\u83c7\u7d20\u7528\u4e8e\u6388\u6743\u7cbe\u795e\u75c5\u533b\u751f\u5f00\u5904\u65b9\u540e\uff0c\u8be5\u4f9b\u5e94\u4e5f\u5c06\u7528\u4e8e\u6f5c\u5728\u7684\u66f4\u5e7f\u6cdb\u7684\u5546\u4e1a\u5316\u3002<\/p>\n<p>\u6839\u636e\u534f\u8bae\uff0cCatalent \u5c06\u6839\u636e\u73b0\u884c\u826f\u597d\u751f\u4ea7\u89c4\u8303 (cGMP) \u6cd5\u89c4\u5f00\u53d1\u548c\u5236\u9020\u836f\u7528\u7ea7\u88f8\u76d6\u83c7\u7d20\u836f\u7269\u3002<\/p>\n<p>\u4f5c\u4e3a\u6d41\u7a0b\u7684\u4e00\u90e8\u5206\uff0cCatalent \u5c06\u5f00\u53d1\u914d\u65b9\uff0c\u5e76\u751f\u6210\u76d1\u7ba1\u5907\u6848\u6240\u9700\u7684\u8d28\u91cf\u548c\u7a33\u5b9a\u6027\u6570\u636e\u3002<\/p>\n<p>Catalent \u5c06\u8bbe\u8ba1\u5236\u9020\u8fc7\u7a0b\uff0c\u4ee5\u4fbf\u5728\u9700\u8981\u65f6\u53ef\u4ee5\u6269\u5c55\u5230\u5546\u4e1a\u89c4\u6a21\u6c34\u5e73\u3002<\/p>\n<p>\u4e00\u65e6\u751f\u4ea7\u51fa\u6765\uff0cIncannex \u5c06\u9996\u5148\u5728\u5176\u6b63\u5728\u8fdb\u884c\u7684\u4e13\u6709\u88f8\u76d6\u83c7\u7d20\u8f85\u52a9\u5fc3\u7406\u6cbb\u7597\u836f\u7269\u5f00\u53d1\u8ba1\u5212\u4e2d\u4f7f\u7528\u8be5\u836f\u7269\u3002<\/p>\n<p>Incannex \u8463\u4e8b\u603b\u7ecf\u7406\u517c\u9996\u5e2d\u6267\u884c\u5b98 Joel Latham \u8868\u793a\uff0c\u4e0e Catalent \u8fbe\u6210\u7684\u534f\u8bae\u5c06\u4e3a\u8be5\u516c\u53f8\u63d0\u4f9b\u81ea\u5df1\u7684\u836f\u7269\u7ea7\u88f8\u76d6\u83c7\u7d20\u6765\u6e90\uff0c\u7528\u4e8e\u5176\u4e34\u5e8a\u8bd5\u9a8c\u548c\u201c\u8bb8\u591a\u5546\u4e1a\u673a\u4f1a\u201d\u3002<\/p>\n<p>Latham \u5148\u751f\u8865\u5145\u8bf4\uff0c\u5546\u4e1a\u673a\u4f1a\u5904\u4e8e\u201c\u8c03\u67e5\u7684\u540e\u671f\u9636\u6bb5\u201d\uff0c\u5c06\u5728\u8463\u4e8b\u4f1a\u8bc4\u4f30\u548c\u6279\u51c6\u540e\u201c\u5728\u672a\u6765\u51e0\u5468\u5185\u201d\u5ba3\u5e03\u3002<\/p>\n<h2>\u88f8\u76d6\u83c7\u7d20\u8f85\u52a9\u5fc3\u7406\u6cbb\u7597\u4e34\u5e8a\u8bd5\u9a8c<\/h2>\n<p>Incannex \u5df2\u7ecf\u542f\u52a8\u4e86\u4e00\u9879\u6b63\u5728\u8fdb\u884c\u7684\u88f8\u76d6\u83c7\u7d20\u8f85\u52a9\u5fc3\u7406\u6cbb\u7597\u4e34\u5e8a\u8bd5\u9a8c\u8ba1\u5212\uff0c\u7528\u4e8e\u6cbb\u7597\u5e7f\u6cdb\u6027\u7126\u8651\u75c7\uff08PsiGAD\uff09\u3002<\/p>\n<p>\u5bf9\u7b2c\u4e8c\u9636\u6bb5 PsiGAD \u8bd5\u9a8c\u7684\u4e2d\u671f\u6570\u636e\u7684\u5ba1\u67e5\u4f7f Incannex \u6709\u4fe1\u5fc3\u7ee7\u7eed\u8058\u8bf7 Catalent \u6765\u914d\u5236\u548c\u5236\u9020\u8be5\u836f\u7269\u3002<\/p>\n<p>\u5728\u8be5\u8bd5\u9a8c\u5b9e\u73b0\u4e86 29 \u540d\u60a3\u8005\u5b8c\u6210\u4e3b\u8981\u7ec8\u70b9\u8bc4\u4f30\u7684\u4e2d\u671f\u91cc\u7a0b\u7891\u4e4b\u540e\uff0c\u8be5\u5ba1\u67e5\u4e8e\u4eca\u5e74 1 \u6708\u5f00\u59cb\u3002<\/p>\n<p>PsiGAD \u8bd5\u9a8c\u662f\u4e0e\u83ab\u7eb3\u4ec0\u5927\u5b66\u4e34\u5e8a\u8ff7\u5e7b\u5b9e\u9a8c\u5ba4\u8d1f\u8d23\u4eba Paul Liknaitzky \u535a\u58eb\u5408\u4f5c\u5f00\u53d1\u7684\u3002<\/p>\n<p>Liknaitzky \u535a\u58eb\u4e5f\u662f Incannex \u79d1\u5b66\u987e\u95ee\u59d4\u5458\u4f1a\u7684\u6210\u5458\u3002<\/p>\n<p>PsiGAD \u7814\u7a76\u5305\u62ec\u5728\u83ab\u7eb3\u4ec0\u5927\u5b66 BrainPark \u8fdb\u884c\u7684\u4e3a\u671f 10 \u5468\u7684\u6cbb\u7597\u8ba1\u5212\u3002 \u6cbb\u7597\u65b9\u6848\u5305\u62ec\u4f7f\u7528\u88f8\u76d6\u83c7\u7d20\u6216\u6d3b\u6027\u5b89\u6170\u5242\u7684\u4e24\u6b21\u7ed9\u836f\u7597\u7a0b\u3002<\/p>\n<p>\u5230 1 \u6708\u5e95\uff0c\u5df2\u6709 45 \u540d\u53c2\u4e0e\u8005\u53c2\u52a0\u4e86\u8bd5\u9a8c\uff0c\u8bd5\u9a8c\u7ee7\u7eed\u6309\u65f6\u987a\u5229\u8fdb\u884c\uff0c\u6ca1\u6709\u51fa\u73b0\u5b89\u5168\u95ee\u9898\u3002<\/p>\n<p>\u4f5c\u4e3a\u7814\u7a76\u7684\u4e00\u90e8\u5206\uff0c\u6b63\u5728\u8bc4\u4f30\u5b89\u5168\u6027\u3001\u6709\u6548\u6027\u3001\u751f\u6d3b\u8d28\u91cf\u548c\u8eab\u5fc3\u5065\u5eb7\u7684\u5176\u4ed6\u65b9\u9762\u3002<\/p>\n<p>Incannex \u7684\u9996\u5e2d\u79d1\u5b66\u5b98 Mark Bleackley \u535a\u58eb\u8868\u793a\uff0c\u8be5\u516c\u53f8\u7684\u7597\u6cd5\u53ef\u80fd\u4f1a\u5e2e\u52a9\u6570\u767e\u4e07\u751f\u6d3b\u53d7\u5230\u4e25\u91cd\u7126\u8651\u5f71\u54cd\u4e14\u5f53\u524d\u9009\u62e9\u65e0\u6548\u7684\u4eba\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Incannex Healthcare (ASX: IHL) \u901a\u8fc7\u8058\u8bf7 Catalent \u6765\u914d\u5236\u548c\u5236\u9020\u7528\u4e8e\u4e34\u5e8a\u8bd5\u9a8c\u7684\u836f\u7269\uff0c\u4ece\u800c\u5728\u5f00\u53d1\u88f8\u76d6\u83c7\u7d20\u836f\u7269\u4ea7\u54c1\u65b9\u9762\u8fbe\u5230\u4e86\u53e6\u4e00\u4e2a\u91cc\u7a0b\u7891\u3002 Incannex \u8fd8\u8868\u793a\uff0c\u5728\u6fb3\u5927\u5229\u4e9a\u76d1\u7ba1\u673a\u6784\u6cbb\u7597\u5546\u54c1\u7ba1\u7406\u5c40 (TGA) \u4ece\u4eca\u5e74 7 \u6708 1 \u65e5\u5f00\u59cb\u5c06\u88f8\u76d6\u83c7\u7d20\u7528\u4e8e\u6388\u6743\u7cbe\u795e\u75c5\u533b\u751f\u5f00\u5904\u65b9\u540e\uff0c\u8be5\u4f9b\u5e94\u4e5f\u5c06\u7528\u4e8e\u6f5c\u5728\u7684\u66f4\u5e7f\u6cdb\u7684\u5546\u4e1a\u5316\u3002 \u6839\u636e\u534f\u8bae\uff0cCatalent \u5c06\u6839\u636e\u73b0\u884c\u826f\u597d\u751f\u4ea7\u89c4\u8303 (cGMP) \u6cd5\u89c4\u5f00\u53d1\u548c\u5236\u9020\u836f\u7528\u7ea7\u88f8\u76d6\u83c7\u7d20\u836f\u7269\u3002 \u4f5c\u4e3a\u6d41\u7a0b\u7684\u4e00\u90e8\u5206\uff0cCatalent \u5c06\u5f00\u53d1\u914d\u65b9\uff0c\u5e76\u751f\u6210\u76d1\u7ba1\u5907\u6848\u6240\u9700\u7684\u8d28\u91cf\u548c\u7a33\u5b9a\u6027\u6570\u636e\u3002 Catalent \u5c06\u8bbe\u8ba1\u5236\u9020\u8fc7\u7a0b\uff0c\u4ee5\u4fbf\u5728\u9700\u8981\u65f6\u53ef\u4ee5\u6269\u5c55\u5230\u5546\u4e1a\u89c4\u6a21\u6c34\u5e73\u3002 \u4e00\u65e6\u751f\u4ea7\u51fa\u6765\uff0cIncannex \u5c06\u9996\u5148\u5728\u5176\u6b63\u5728\u8fdb\u884c\u7684\u4e13\u6709\u88f8\u76d6\u83c7\u7d20\u8f85\u52a9\u5fc3\u7406\u6cbb\u7597\u836f\u7269\u5f00\u53d1\u8ba1\u5212\u4e2d\u4f7f\u7528\u8be5\u836f\u7269\u3002 Incannex \u8463\u4e8b\u603b\u7ecf\u7406\u517c\u9996\u5e2d\u6267\u884c\u5b98 Joel Latham \u8868\u793a\uff0c\u4e0e Catalent \u8fbe\u6210\u7684\u534f\u8bae\u5c06\u4e3a\u8be5\u516c\u53f8\u63d0\u4f9b\u81ea\u5df1\u7684\u836f\u7269\u7ea7\u88f8\u76d6\u83c7\u7d20\u6765\u6e90\uff0c\u7528\u4e8e\u5176\u4e34\u5e8a\u8bd5\u9a8c\u548c\u201c\u8bb8\u591a\u5546\u4e1a\u673a\u4f1a\u201d\u3002 Latham \u5148\u751f\u8865\u5145\u8bf4\uff0c\u5546\u4e1a\u673a\u4f1a\u5904\u4e8e\u201c\u8c03\u67e5\u7684\u540e\u671f\u9636\u6bb5\u201d\uff0c\u5c06\u5728\u8463\u4e8b\u4f1a\u8bc4\u4f30\u548c\u6279\u51c6\u540e\u201c\u5728\u672a\u6765\u51e0\u5468\u5185\u201d\u5ba3\u5e03\u3002 \u88f8\u76d6\u83c7\u7d20\u8f85\u52a9\u5fc3\u7406\u6cbb\u7597\u4e34\u5e8a\u8bd5\u9a8c Incannex \u5df2\u7ecf\u542f\u52a8\u4e86\u4e00\u9879\u6b63\u5728\u8fdb\u884c\u7684\u88f8\u76d6\u83c7\u7d20\u8f85\u52a9\u5fc3\u7406\u6cbb\u7597\u4e34\u5e8a\u8bd5\u9a8c\u8ba1\u5212\uff0c\u7528\u4e8e\u6cbb\u7597\u5e7f\u6cdb\u6027\u7126\u8651\u75c7\uff08PsiGAD\uff09\u3002 \u5bf9\u7b2c\u4e8c\u9636\u6bb5 PsiGAD \u8bd5\u9a8c\u7684\u4e2d\u671f\u6570\u636e\u7684\u5ba1\u67e5\u4f7f Incannex \u6709\u4fe1\u5fc3\u7ee7\u7eed\u8058\u8bf7 Catalent \u6765\u914d\u5236\u548c\u5236\u9020\u8be5\u836f\u7269\u3002 \u5728\u8be5\u8bd5\u9a8c\u5b9e\u73b0\u4e86 29 \u540d\u60a3\u8005\u5b8c\u6210\u4e3b\u8981\u7ec8\u70b9\u8bc4\u4f30\u7684\u4e2d\u671f\u91cc\u7a0b\u7891\u4e4b\u540e\uff0c\u8be5\u5ba1\u67e5\u4e8e\u4eca\u5e74 1 \u6708\u5f00\u59cb\u3002 PsiGAD \u8bd5\u9a8c\u662f\u4e0e\u83ab\u7eb3\u4ec0\u5927\u5b66\u4e34\u5e8a\u8ff7\u5e7b\u5b9e\u9a8c\u5ba4\u8d1f\u8d23\u4eba Paul Liknaitzky \u535a\u58eb\u5408\u4f5c\u5f00\u53d1\u7684\u3002 Liknaitzky&hellip; <a class=\"more-link\" href=\"https:\/\/smallcapscn.x5view.co\/?p=6501\">Continue reading <span class=\"screen-reader-text\">Incannex Healthcare \u9501\u5b9a\u81ea\u5df1\u7684\u88f8\u76d6\u83c7\u7d20\u836f\u7269\u4f9b\u5e94\uff0c\u7528\u4e8e\u4e34\u5e8a\u8bd5\u9a8c\u548c\u6f5c\u5728\u5546\u4e1a\u5316<\/span><\/a><\/p>\n","protected":false},"author":3,"featured_media":18834,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[33],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v17.3 (Yoast SEO v21.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Incannex Healthcare \u9501\u5b9a\u81ea\u5df1\u7684\u88f8\u76d6\u83c7\u7d20\u836f\u7269\u4f9b\u5e94\uff0c\u7528\u4e8e\u4e34\u5e8a\u8bd5\u9a8c\u548c\u6f5c\u5728\u5546\u4e1a\u5316<\/title>\n<meta name=\"description\" content=\"Incannex Healthcare (ASX: IHL) \u901a\u8fc7\u8058\u8bf7 Catalent \u6765\u914d\u5236\u548c\u5236\u9020\u7528\u4e8e\u4e34\u5e8a\u8bd5\u9a8c\u7684\u836f\u7269\uff0c\u4ece\u800c\u5728\u5f00\u53d1\u88f8\u76d6\u83c7\u7d20\u836f\u7269\u4ea7\u54c1\u65b9\u9762\u8fbe\u5230\u4e86\u53e6\u4e00\u4e2a\u91cc\u7a0b\u7891\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Incannex Healthcare \u9501\u5b9a\u81ea\u5df1\u7684\u88f8\u76d6\u83c7\u7d20\u836f\u7269\u4f9b\u5e94\uff0c\u7528\u4e8e\u4e34\u5e8a\u8bd5\u9a8c\u548c\u6f5c\u5728\u5546\u4e1a\u5316\" \/>\n<meta property=\"og:description\" content=\"Incannex Healthcare (ASX: IHL) \u901a\u8fc7\u8058\u8bf7 Catalent \u6765\u914d\u5236\u548c\u5236\u9020\u7528\u4e8e\u4e34\u5e8a\u8bd5\u9a8c\u7684\u836f\u7269\uff0c\u4ece\u800c\u5728\u5f00\u53d1\u88f8\u76d6\u83c7\u7d20\u836f\u7269\u4ea7\u54c1\u65b9\u9762\u8fbe\u5230\u4e86\u53e6\u4e00\u4e2a\u91cc\u7a0b\u7891\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/incannex-healthcare-engages-catalent-develop-psilocybin-drug-clinical-trials-commercialisation\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-03T00:33:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T17:57:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Incannex-Healthcare-ASX-IHL-Catalent-cGMP-grade-psilocybin-drug-clinical-trials.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Lorna Nicholas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lorna Nicholas\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/incannex-healthcare-engages-catalent-develop-psilocybin-drug-clinical-trials-commercialisation\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/incannex-healthcare-engages-catalent-develop-psilocybin-drug-clinical-trials-commercialisation\/\",\"name\":\"Incannex Healthcare \u9501\u5b9a\u81ea\u5df1\u7684\u88f8\u76d6\u83c7\u7d20\u836f\u7269\u4f9b\u5e94\uff0c\u7528\u4e8e\u4e34\u5e8a\u8bd5\u9a8c\u548c\u6f5c\u5728\u5546\u4e1a\u5316\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2023-03-03T00:33:15+00:00\",\"dateModified\":\"2023-08-29T17:57:11+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60\"},\"description\":\"Incannex Healthcare (ASX: IHL) \u901a\u8fc7\u8058\u8bf7 Catalent \u6765\u914d\u5236\u548c\u5236\u9020\u7528\u4e8e\u4e34\u5e8a\u8bd5\u9a8c\u7684\u836f\u7269\uff0c\u4ece\u800c\u5728\u5f00\u53d1\u88f8\u76d6\u83c7\u7d20\u836f\u7269\u4ea7\u54c1\u65b9\u9762\u8fbe\u5230\u4e86\u53e6\u4e00\u4e2a\u91cc\u7a0b\u7891\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/incannex-healthcare-engages-catalent-develop-psilocybin-drug-clinical-trials-commercialisation\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/incannex-healthcare-engages-catalent-develop-psilocybin-drug-clinical-trials-commercialisation\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/incannex-healthcare-engages-catalent-develop-psilocybin-drug-clinical-trials-commercialisation\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Incannex Healthcare \u9501\u5b9a\u81ea\u5df1\u7684\u88f8\u76d6\u83c7\u7d20\u836f\u7269\u4f9b\u5e94\uff0c\u7528\u4e8e\u4e34\u5e8a\u8bd5\u9a8c\u548c\u6f5c\u5728\u5546\u4e1a\u5316\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60\",\"name\":\"Lorna Nicholas\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g\",\"caption\":\"Lorna Nicholas\"},\"description\":\"Lorna has more than 15 years' experience as a business\/finance journalist and editor. She has written for numerous industry publications reporting on various sectors, including: resources, energy, construction, biotech, pharma, science and technology, agriculture, and chemicals. Specialising in resources, Lorna has also covered a myriad of small and large cap ASX and dual-listed stocks.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=3\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Incannex Healthcare \u9501\u5b9a\u81ea\u5df1\u7684\u88f8\u76d6\u83c7\u7d20\u836f\u7269\u4f9b\u5e94\uff0c\u7528\u4e8e\u4e34\u5e8a\u8bd5\u9a8c\u548c\u6f5c\u5728\u5546\u4e1a\u5316","description":"Incannex Healthcare (ASX: IHL) \u901a\u8fc7\u8058\u8bf7 Catalent \u6765\u914d\u5236\u548c\u5236\u9020\u7528\u4e8e\u4e34\u5e8a\u8bd5\u9a8c\u7684\u836f\u7269\uff0c\u4ece\u800c\u5728\u5f00\u53d1\u88f8\u76d6\u83c7\u7d20\u836f\u7269\u4ea7\u54c1\u65b9\u9762\u8fbe\u5230\u4e86\u53e6\u4e00\u4e2a\u91cc\u7a0b\u7891\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Incannex Healthcare \u9501\u5b9a\u81ea\u5df1\u7684\u88f8\u76d6\u83c7\u7d20\u836f\u7269\u4f9b\u5e94\uff0c\u7528\u4e8e\u4e34\u5e8a\u8bd5\u9a8c\u548c\u6f5c\u5728\u5546\u4e1a\u5316","og_description":"Incannex Healthcare (ASX: IHL) \u901a\u8fc7\u8058\u8bf7 Catalent \u6765\u914d\u5236\u548c\u5236\u9020\u7528\u4e8e\u4e34\u5e8a\u8bd5\u9a8c\u7684\u836f\u7269\uff0c\u4ece\u800c\u5728\u5f00\u53d1\u88f8\u76d6\u83c7\u7d20\u836f\u7269\u4ea7\u54c1\u65b9\u9762\u8fbe\u5230\u4e86\u53e6\u4e00\u4e2a\u91cc\u7a0b\u7891\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/incannex-healthcare-engages-catalent-develop-psilocybin-drug-clinical-trials-commercialisation\/","og_site_name":"smallcapsCN","article_published_time":"2023-03-03T00:33:15+00:00","article_modified_time":"2023-08-29T17:57:11+00:00","og_image":[{"width":640,"height":400,"url":"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Incannex-Healthcare-ASX-IHL-Catalent-cGMP-grade-psilocybin-drug-clinical-trials.jpg","type":"image\/jpeg"}],"author":"Lorna Nicholas","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Lorna Nicholas"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/incannex-healthcare-engages-catalent-develop-psilocybin-drug-clinical-trials-commercialisation\/","url":"https:\/\/smallcapscn.x5view.co\/incannex-healthcare-engages-catalent-develop-psilocybin-drug-clinical-trials-commercialisation\/","name":"Incannex Healthcare \u9501\u5b9a\u81ea\u5df1\u7684\u88f8\u76d6\u83c7\u7d20\u836f\u7269\u4f9b\u5e94\uff0c\u7528\u4e8e\u4e34\u5e8a\u8bd5\u9a8c\u548c\u6f5c\u5728\u5546\u4e1a\u5316","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2023-03-03T00:33:15+00:00","dateModified":"2023-08-29T17:57:11+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60"},"description":"Incannex Healthcare (ASX: IHL) \u901a\u8fc7\u8058\u8bf7 Catalent \u6765\u914d\u5236\u548c\u5236\u9020\u7528\u4e8e\u4e34\u5e8a\u8bd5\u9a8c\u7684\u836f\u7269\uff0c\u4ece\u800c\u5728\u5f00\u53d1\u88f8\u76d6\u83c7\u7d20\u836f\u7269\u4ea7\u54c1\u65b9\u9762\u8fbe\u5230\u4e86\u53e6\u4e00\u4e2a\u91cc\u7a0b\u7891\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/incannex-healthcare-engages-catalent-develop-psilocybin-drug-clinical-trials-commercialisation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/incannex-healthcare-engages-catalent-develop-psilocybin-drug-clinical-trials-commercialisation\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/incannex-healthcare-engages-catalent-develop-psilocybin-drug-clinical-trials-commercialisation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"Incannex Healthcare \u9501\u5b9a\u81ea\u5df1\u7684\u88f8\u76d6\u83c7\u7d20\u836f\u7269\u4f9b\u5e94\uff0c\u7528\u4e8e\u4e34\u5e8a\u8bd5\u9a8c\u548c\u6f5c\u5728\u5546\u4e1a\u5316"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60","name":"Lorna Nicholas","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g","caption":"Lorna Nicholas"},"description":"Lorna has more than 15 years' experience as a business\/finance journalist and editor. She has written for numerous industry publications reporting on various sectors, including: resources, energy, construction, biotech, pharma, science and technology, agriculture, and chemicals. Specialising in resources, Lorna has also covered a myriad of small and large cap ASX and dual-listed stocks.","url":"https:\/\/smallcapscn.x5view.co\/?author=3"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/6501"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6501"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/6501\/revisions"}],"predecessor-version":[{"id":20299,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/6501\/revisions\/20299"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/18834"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6501"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6501"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6501"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}